Annual Sales of Tenofovir Hydrate reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

AAPS 2024

Not Confirmed

Brand Name : Stribild

AAPS 2024

Not Confirmed

U.S.A

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Gilead

Tenofovir

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2022 Revenue in Millions : 127

2021 Revenue in Millions : 189

Growth (%) : -33

Portfolio PDF

Product Web Link

Corporate PDF

02 Brand Name : Complera/Eviplera

AAPS 2024

Not Confirmed

Brand Name : Complera/Eviplera

AAPS 2024

Not Confirmed

U.S.A

Gilead

Tenofovir

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2022 Revenue in Millions : 200

2021 Revenue in Millions : 258

Growth (%) : -22

Portfolio PDF

Product Web Link

Corporate PDF

03 Brand Name : Stribild

AAPS 2024

Not Confirmed

Brand Name : Stribild

AAPS 2024

Not Confirmed

U.S.A

Gilead

Tenofovir

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2023 Revenue in Millions : 101

2022 Revenue in Millions : 127

Growth (%) : -20

Portfolio PDF

Product Web Link

Corporate PDF

04 Brand Name : Complera/Eviplera

AAPS 2024

Not Confirmed

Brand Name : Complera/Eviplera

AAPS 2024

Not Confirmed

U.S.A

Gilead

Tenofovir

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2023 Revenue in Millions : 129

2022 Revenue in Millions : 200

Growth (%) : -36

Portfolio PDF

Product Web Link